MedTrace Logo

Effectiveness and Cost-effectiveness of the Initial Medication Adherence Intervention

NCT05026775 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4153

Last updated 2022-10-12

No results posted yet for this study

Summary

The purpose of this study is to assess the effectiveness and the cost-effectiveness of the Initial Medication Adherence (IMA) Intervention.

Conditions

  • Adherence, Medication

Interventions

BEHAVIORAL

Initial Medication Adherence (IMA)

The IMA intervention is a shared-decision making intervention that promotes health literacy and patient participation in the decision making process during the recommendation and prescription of a new drug for the management of a cardiovascular disease and diabetes. The IMA intervention has four main components: training for healthcare professionals (general practitioners (GP), nurses and community pharmacists) on non-initiation, shared-decision making, health literacy and use of decision aids; intervention decision aids (leaflets and website); implementation of the IMA intervention during the GP's consultation; and information support provided by the nurses and community pharmacists that will use the intervention decision aids to explore the patients's doubts and harmonise and standardise the discourse between primary healthcare professionals.

OTHER

Usual care

Health professionals in the usual care group will prescribe medication and provide information as usual.

Sponsors & Collaborators

  • Institut Català de la Salut

    collaborator OTHER

  • Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina

    collaborator OTHER

  • Parc Sanitari Sant Joan de Déu

    collaborator OTHER

  • CIBER of Epidemiology and Public Health

    collaborator UNKNOWN

  • Consell de Col·legis de Farmacèutics de Catalunya

    collaborator UNKNOWN

  • Catalan Society of Family Medicine

    collaborator OTHER

  • Fundació Sant Joan de Déu

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2022-09-30
Completion
2023-09-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05026775 on ClinicalTrials.gov